Research programme: diarylquinolines - Global Alliance of TB Drug Development/Janssen Infectious Diseases BVBA

Drug Profile

Research programme: diarylquinolines - Global Alliance of TB Drug Development/Janssen Infectious Diseases BVBA

Alternative Names: ATP-synthase inhibitors; Diarylquinolines

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Global Alliance for TB Drug Development; Janssen Infectious Diseases BVBA
  • Class Quinolones; Small molecules
  • Mechanism of Action Adenosine triphosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Tuberculosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Tuberculosis in USA (PO)
  • 01 Jan 2009 Early research in Tuberculosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top